The committee is considering three bills aimed at tackling one of the biggest cost drivers in medicine today -- outrageously priced biological wonder drugs. One bill would prevent health insurers from gouging consumers who need these medications. A second bill would require pharmaceuticals to report their profit information to the Oregon Health Authority. The third bill would free pharmacists to dispense FDA-approved biosimilars without special state barriers.
Mar 17, 2015
Premium